Quoin Pharmaceuticals (QNRX) Liabilities and Shareholders Equity (2017 - 2026)

Quoin Pharmaceuticals has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $15.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 21.13% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.4 million (down 4.97% YoY) and the FY2025 annual result came in at $20.4 million, up 29.8% from the prior year.
• Liabilities and Shareholders Equity fell to $15.7 million in Q1 2026 per QNRX's latest filing, from $20.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $20.4 million in Q4 2025 and troughed at $4.3 million in Q2 2022.
• A 5-year average of $13.7 million and a median of $14.8 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity surged 286.68% in 2023, then plunged 43.6% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $14.5 million in 2022, then dropped by 15.83% to $12.2 million in 2023, then increased by 29.09% to $15.7 million in 2024, then gained by 29.8% to $20.4 million in 2025, then dropped by 23.04% to $15.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $15.7 million, $20.4 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.